 EMERYVILLE, Calif., Sept. 20, 2022 GLOBE NEWSWIRE -- 4D Molecular Therapeutics, Inc. Nasdaq: FDMT, a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the following upcoming investor conferences: 